Information Provided By: 
Fly News Breaks for September 19, 2017
MRTX
Sep 19, 2017 | 07:31 EDT
Oppenheimer analyst Leah Rush Cann started Mirati Therapeutics with an Outperform rating and $18 price target as she anticipates several data releases before the end of 2017 that will inform its continued development of its three lead compounds as well as a fourth compound entering clinical development. The analyst estimates that Mirati will first have product revenue in 2022 resulting in total revenue that year of $390.2M, potentially growing to $1.64B in 2023, if all three compounds are successful in currently planned indications.
News For MRTX From the Last 2 Days
There are no results for your query MRTX
